Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 07/13 10:00:17 pm
125.93 USD   -1.43%
07/14JOHNSON & JOHNS : J&J loses big in asbestos suit
07/14JOHNSON & JOHNS : Women warned over use of
07/13CORRECTION : Talc Powder-Cancer Lawsuit story
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : angelMD Invests in Two Startups from the Johnson & Johnson QuickFire Challenge

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 03:37pm CEST

Seattle, Washington (PRWEB) October 05, 2017

Today, angelMD, the world's largest network of healthcare startups, announced investments in LifeSprout and Intelligent Implants, two promising startups identified through angelMD's collaboration with Johnson & Johnson Innovation on the "QuickFire Challenge" competition.

In conjunction with the upcoming grand opening of Johnson & Johnson Innovation's Center for Device Innovation at the Texas Medical Center in Houston (CDI @ TMC), Johnson & Johnson Innovation launched the CDI @ TMC QuickFire Challenge with angelMD to challenge startups to develop early-stage medical device innovations. The CDI @ TMC is the second Johnson & Johnson Innovation facility in Houston, joining the already established JLABS @ TMC.

"Identifying the best science and technology in healthcare is one of our goals at Johnson & Johnson Innovation," said Tom Luby, head of Johnson & Johnson' Innovation's startup accelerator in Houston, JLABS @ TMC. "Joining with partners like angelMD in startup challenges, we hope to find early-stage companies creating new innovations in healthcare, and we will work with these startups to further support their development."

As part of the collaboration with Johnson & Johnson Innovation, the angelMD Catalyst Fund will make a $50,000 investment each in LifeSprout and Intelligent Implants. In addition, angelMD will feature the two startups on its investment platform for angelMD members to invest an additional $250,000 or more in each company. The investments were officially announced by Charlie Emley, Catalyst Fund Managing Partner, at the 2017 MedTech Conference in San Jose, California.

"As the largest network of healthcare startups in the world, we see first-hand the innovation taking place among startups working to create better healthcare outcomes," said Tobin Arthur, co-founder and chief executive officer for angelMD. "We are honored to partner with Johnson & Johnson Innovation's JLABS facility to help identify some of the most promising medical device startups, and we are excited to invest in LifeSprout and Intelligent Implants."

LifeSprout is a startup formed by Russell Martin, Hai-Quan Mao, Justin Sacks, and Dr. Sashank Reddy. Together, this group of engineers, scientists, and clinicians from Johns Hopkins University developed an innovative soft tissue replacement alternative. This synthetic alternative can be used to replace soft tissue lost as a result of various cancers or traumatic incidents.

Intelligent Implants is a startup founded by John Zellmer, Erik Zellmer, Juan Pardo, and Rory Murphy. The team worked to harness the latest advances in electro-therapeutics to speed up, control and monitor bone growth. The Intelligent Implants system is known as "SmartFuse" and represents a novel method of delivering electric current to support the process of bone fusion. With SmartFuse, they can stimulate more where they want bone growth, and stimulate less where it's not needed.

"LifeSprout and Intelligent Implants represent some of the most innovative thinking in healthcare today, and we are excited to invest in these companies' futures," added Arthur. "angelMD will continue to help spur innovation in healthcare by being a partner to ground-breaking startups such as these."

In addition to the CDI @ TMC QuickFire Challenge, angelMD plans to host another startup competition at its upcoming Alpha Conference. More information about the Alpha Conference can be found at: http://www.alphatheconference.com/.

About angelMD
angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit http://www.angelmd.co.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14761625.htm

(c) 2017 PRWEB.COM Newswire, source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
07/15JOHNSON & JOHNSON : to pay $4.7bn damages in talc cancer case
07/14JOHNSON & JOHNSON : J&J loses big in asbestos suit
07/14JOHNSON & JOHNSON : U.S. FDA Extends Review Timeline for INVOKANA(R) (Canagliflo..
07/14JOHNSON & JOHNSON : Women warned over use of
07/14JOHNSON & JOHNSON : £3.6bn pay-out in talcum case
07/14JOHNSON & JOHNSON : 's Issues Response to Verdict in St. Louis Trial
07/13CORRECTION : Talc Powder-Cancer Lawsuit story
07/13JOHNSON & JOHNSON : U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozi..
07/13JOHNSON & JOHNSON : J&J vows to overturn $4.7 billion talc verdict but experts s..
07/13JOHNSON & JOHNSON : Supervisor House defends past dealings with Johnson Utilitie..
More news
News from SeekingAlpha
07/15JOHNSON & JOHNSON : Floodgates And Tidal Waves 
07/14Johnson & Johnson Is Recovering From Talcum Powder Correction, Faces Earnings 
07/14RETIREMENT STRATEGY : The "Best" Of Regarded Solutions And Dividend Growth Inves.. 
07/14STOCKS TO WATCH : Prime Time In Retail 
07/13Law experts see challenges in J&J appeal of $4.7B talc verdict 
Financials ($)
Sales 2018 81 514 M
EBIT 2018 24 880 M
Net income 2018 16 947 M
Debt 2018 10 661 M
Yield 2018 2,85%
P/E ratio 2018 18,25
P/E ratio 2019 16,84
EV / Sales 2018 4,27x
EV / Sales 2019 3,98x
Capitalization 338 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 142 $
Spread / Average Target 13%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.59%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193
AMGEN11.60%129 635